-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

623.O1.6 623. Mantle Cell and Indolent B-Cell Lymphoma - CAR-T and immunotherapy clinical studies

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological, antibodies, Adult, CRS, Follicular Lymphoma, Diseases, Lymphoma (any), Marginal Zone Lymphoma, Non-Biological, CAR-Ts, Therapies, Combinations, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, pharmacology
Monday, December 7, 2020: 1:30 PM-3:00 PM
Adrienne A. Phillips, MD, Weill Cornell Medicine and Tycel J. Phillips, MD, University of Michigan Cancer Center
No relevant conflicts of interest to declare.
1:30 PM

Caron Jacobson, MD, MMSc1, Julio C. Chavez, MD2, Alison R. Sehgal, MD3, Basem M. William, MD, MRCP4, Javier Munoz, MD5, Gilles Salles, MD, PhD6, Pashna N. Munshi, MD7, Carla Casulo, MD8, David Maloney, MD, PhD9, Sven de Vos, MD, PhD10, Ran Reshef, MD11, Lori A. Leslie, MD12, Ibrahim Yakoub-Agha13, Olalekan O. Oluwole, MBBS, MPH14, Henry C.H. Fung, MD15*, Joseph D. Rosenblatt, MD16, John M. Rossi, MS17*, Lovely Goyal, PhD17*, Vicki Plaks, LLB, PhD17*, Yin Yang, MS17*, Jennifer Lee, BS17*, Wayne Godfrey, MD17, Remus Vezan, MD, PhD17, Mauro P. Avanzi, MD, PhD17* and Sattva S. Neelapu, MD18

1Dana Faber Cancer Institute, Harvard Medical School, Boston, MA
2University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3UPMC Hillman Cancer Center, Pittsburgh, PA
4The Ohio State University Comprehensive Cancer Center, Columbus, OH
5Banner MD Anderson Cancer Center, Gilbert, AZ
6Centre Hospitalier Lyon-Sud, Pierre-Benite, France
7Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
8University of Rochester Medical Center - James P. Wilmot Cancer Center, Rochester, NY
9Fred Hutchinson Cancer Research Center, Seattle, WA
10Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
11Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY
12Lymphoma Research Division, John Theurer Cancer Center, Hackensack, NJ
13CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
14Vanderbilt University Medical Center, Nashville, TN
15Fox Chase Cancer Center, Phladelphia
16University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
17Kite, a Gilead Company, Santa Monica, CA
18The University of Texas MD Anderson Cancer Center, Houston, TX

1:45 PM

Francisco J. Hernandez-Ilizaliturri, MD1, Ian W. Flinn, MD, PhD2, John Kuruvilla, MD3, Sarit E Assouline, MD, MSc4, Matthew L. Ulrickson, MD5, Beth A. Christian, MD6, Daniel J. Landsburg, MD7, Monic Stuart, MD, MPH8, Henry Lowman, PhD9* and Nancy Levin, PhD9*

1Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
3The Princess Margaret Hospital, Toronto, ON, Canada
4Division of Hematology, Sir Mortimer B. Davis-Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada
5Banner MD Anderson Cancer Center, Gilbert, AZ
6The Ohio State University, Columbus, OH
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Clinical Drug Development Consultants LLC, Hillsborough, CA
9Triphase Accelerator, La Jolla, CA

2:00 PM

Sarit E Assouline, MD, MSc1, Won Seog Kim, MD, PhD2*, Laurie H. Sehn, MD, MPH3, Stephen J. Schuster, MD4, Chan Yoon Cheah, MBBS5, Loretta J. Nastoupil, MD6, Mazyar Shadman7, Sung-Soo Yoon, MD, PhD8, Matthew J Matasar, MD, MS9, Catherine Diefenbach, MD10, Gareth P. Gregory11, Nancy L. Bartlett, MD12*, Michael C. Wei13*, Michelle Y. Doral13*, Shen Yin13*, Raluca Negricea14*, Chi-Chung Li13*, Elicia M. Penuel13*, Huang Huang14* and L. Elizabeth Budde15

1Jewish General Hospital, Montreal, QC, Canada
2Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)
3BC Cancer Centre for Lymphoid Cancer, University of British Columbia, vancouver, BC, Canada
4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
5Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia
6MD Anderson Cancer Center, Houston, TX
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
9Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
10Perlmutter Cancer Center at NYU Langone Health, New York, NY
11School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
12Department of Medicine, Washington University School of Medicine, St. Louis, MO
13Genentech, Inc., South San Francisco, CA
14F. Hoffmann-La Roche Limited, Mississauga, ON, Canada
15City of Hope, Duarte, CA

2:15 PM

Grzegorz S. Nowakowski, MD1, Lori A. Leslie, MD2, Anas Younes, MD3, Allison C. Rosenthal, D.O.4, Matthew A. Lunning, DO, FACP5, Krish Patel, MD6, Daniel J. Landsburg, MD7, Elizabeth Martinez, PhD, DHSC, MSN8*, Reinhard von Roemeling, MD9, Christopher Lieberman10* and Han W. Tun, MD11

1Division of Hematology, Mayo Clinic, Rochester, MN
2John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
3Memorial Sloan Kettering Cancer Center, New York City, NY
4Mayo Clinic, Phoenix, AZ
5University of Nebraska Medical Center, Omaha, NE
6Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Curis Inc., Lexington, MA
9Curis, Inc., Lexington, MA
10Curis, Inc, Lexington, MA
11Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL

2:30 PM

Samuel Yamshon, MD1, Peter Martin, FRCPC, MD, MS2, Bijal Shah, MD3, Stephen J. Schuster, MD4, Paul J Christos, Dr.P.H., M.S.5*, Amelyn Rodriguez, BSN, RN, OCN6*, Sonali M. Smith, MD7, Jakub Svoboda, MD8, Richard R. Furman, MD9, Sarah C. Rutherford, MD9, John N. Allan, MD10, John P. Leonard, MD2 and Jia Ruan, MD, PhD2

1Department of Hematology/Oncology, Weill-Cornell Medicine, New York, NY
2Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
3Moffitt Cancer Center, Tampa, FL
4Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
5Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY
6Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY
7Department of Oncology, University of Chicago, Chicago, IL
8Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
9Meyer Cancer Center, Weill Cornell Medicine, New York, NY
10Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY

*signifies non-member of ASH